BRAF and thyroid gland carcinoma: Likewise, phase II clinical trials have demonstrated noteworthy response rates in advanced BRAF-mutated thyroid carcinomas when treated with a combination of the BRAF inhibitor dabrafenib and MEK inhibitor trametinib [69].